Amylyx Pharmaceuticals Inc’s recent filing unveils that its Chief Financial Officer FRATES JAMES M unloaded Company’s shares for reported $37806.0 on Mar 31 ’25. In the deal valued at $3.47 per share,10,896 shares were sold. As a result of this transaction, FRATES JAMES M now holds 290,988 shares worth roughly $1.43 million.
Then, Bedrosian Camille L sold 12,425 shares, generating $43,082 in total proceeds. Upon selling the shares at $3.47, the Chief Medical Officer now owns 194,375 shares.
Before that, Mazzariello Gina sold 9,192 shares. Amylyx Pharmaceuticals Inc shares valued at $31,954 were divested by the Chief Legal Officer at a price of $3.48 per share. As a result of the transaction, Mazzariello Gina now holds 187,969 shares, worth roughly $0.92 million.
Mizuho upgraded its Amylyx Pharmaceuticals Inc [AMLX] rating to an Outperform from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who increased its forecast for the stock in mid November from “a Neutral” to “an Outperform”. BofA Securities also remained covering AMLX and has increased its forecast on October 23, 2024 with a “Buy” recommendation from previously “Neutral” rating. Mizuho revised its rating on March 18, 2024. It rated AMLX as “a Neutral” which previously was an “a Buy”.
Price Performance Review of AMLX
On Tuesday, Amylyx Pharmaceuticals Inc [NASDAQ:AMLX] saw its stock fall -2.20% to $4.90. Over the last five days, the stock has lost -0.41%. Amylyx Pharmaceuticals Inc shares have risen nearly 29.63% since the year began. Nevertheless, the stocks have risen 175.28% over the past one year. While a 52-week high of $7.27 was reached on 04/25/25, a 52-week low of $1.58 was recorded on 03/04/25. SMA at 50 days reached $3.75, while 200 days put it at $3.63.
Levels Of Support And Resistance For AMLX Stock
The 24-hour chart illustrates a support level at 4.75, which if violated will result in even more drops to 4.59. On the upside, there is a resistance level at 5.09. A further resistance level may holdings at 5.27. The Relative Strength Index (RSI) on the 14-day chart is 64.98, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.74, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 23.99%. Stochastics %K at 84.08% indicates the stock is a selling.
How much short interest is there in Amylyx Pharmaceuticals Inc?
A steep rise in short interest was recorded in Amylyx Pharmaceuticals Inc stocks on 2025-04-15, growing by 0.56 million shares to a total of 4.31 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-14 was 3.75 million shares. There was a rise of 13.1%, which implies that there is a positive sentiment for the stock.
